R
2R3
vs
NOVN
NOVN
Over the past 12 months, 2R3 has underperformed NOVN, delivering a return of 0% compared to the NOVN's +31% growth.
Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
Smart Verdict
AI-Powered
Let AI Decide.
NOVN
Valuation Comparison
| Company | Last Price | Intrinsic Value | DCF Value | Relative Value | Wall St Target | ||
|---|---|---|---|---|---|---|---|
|
R
|
Reata Pharmaceuticals Inc
F:2R3
|
161
EUR
|
|||||
|
Novartis AG
SIX:NOVN
|
129.9
CHF
|
|||||
Compare the stock's valuation with its competitors.
Growth Comparison
Growth Over Time
2R3, NOVN
Compare company's financials with its competitors.
| Company | LTM | Historical Growth | Growth Streak | % Positive Years | Max Drawdown | Volatility | Forecasted Growth | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3 Years | 5 Years | 10 Years | 1 Year | 3 Years | ||||||||
|
R
|
Reata Pharmaceuticals Inc
Revenue
|
|||||||||||
|
|
Novartis AG
Revenue
|
|||||||||||
All metrics are calculated based on data from the last 10 years.
Compare company's financials with its competitors.
Profitability Comparison
Free Cash Flow
2R3, NOVN
Compare company's free cash flow with its competitors.
| Company | LTM | Average | Historical Growth | FCF Margin | Conversion | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| 3 Years | 5 Years | 3 Years | 5 Years | 10 Years | ||||||
|
R
|
Reata Pharmaceuticals Inc
F:2R3
|
|||||||||
|
|
Novartis AG
SIX:NOVN
|
|||||||||
Compare company's free cash flow with its competitors.
Operating Margin
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
R
|
Reata Pharmaceuticals Inc | ||||
|
|
Novartis AG | ||||
FCF Margin
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
R
|
Reata Pharmaceuticals Inc | ||||
|
|
Novartis AG | ||||
Solvency Comparison
Compare company's equity waterfall with its competitors.
Stocks Performance
Stocks Performance
2R3, NOVN
Performance By Year
2R3, NOVN
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
| US |
|
Eli Lilly and Co
NYSE:LLY
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
